Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) announced its financial results for the full year ended December 31, 2025, alongside a corporate update following its acquisition of Faeth Therapeutics. The company reported a net loss of $21.1 million, or $(16.72) per share, a decrease from the previous year's net loss of $30.2 million. The decrease in losses is attributed to reduced research and development expenses, which fell to $11.0 million from $18.6 million in 2024. General and administrative expenses also decreased to $11.3 million from $13.0 million. The company ended the year with $21.2 million in cash and cash equivalents, down from $41.3 million in 2024. Sensei's acquisition of Faeth Therapeutics and a concurrent $200 million private placement are expected to support the advancement of its lead program, PIKTOR, through key clinical milestones in endometrial and breast cancer. The company aims to achieve topline data from ongoing trials by the end of 2026, highlighting its focus on disciplined execution and addressing significant unmet needs in oncology.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.